Acorda Therapeutics Inc  

(Public, NASDAQ:ACOR)   Watch this stock  
Find more results for ACOR
36.50
+0.09 (0.25%)
Nov 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 35.90 - 36.55
52 week 27.51 - 39.94
Open 36.42
Vol / Avg. 415,888.00/530,711.00
Mkt cap 1.53B
P/E 65.60
Div/yield     -
EPS 0.56
Shares 41.95M
Beta 1.36
Inst. own 108%
Feb 11, 2015
Q4 2014 Acorda Therapeutics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 18, 2014
Acorda Therapeutics Inc at Stifel Healthcare Conference
Nov 11, 2014
Acorda Therapeutics Inc at Credit Suisse Healthcare Conference
Oct 30, 2014
Q3 2014 Acorda Therapeutics Inc Earnings Release
Oct 30, 2014
Q3 2014 Acorda Therapeutics Inc Earnings Call
Sep 24, 2014
Acorda Therapeutics to Acquire Civitas Therapeutics Conference Call - Webcast
Sep 11, 2014
Acorda Therapeutics Inc at Aegis Capital Corp Healthcare & Technology Conference
Sep 9, 2014
Acorda Therapeutics Inc at Morgan Stanley Healthcare Conference
Sep 4, 2014
Acorda Therapeutics Inc at Robert W. Baird & Co. Inc Health Care Conference
Sep 3, 2014
Acorda Therapeutics Inc at Citi Biotech Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 11.28% 4.89%
Operating margin 19.66% 9.03%
EBITD margin - 11.11%
Return on average assets 5.00% 2.80%
Return on average equity 9.37% 3.98%
Employees 421 -
CDP Score - -

Address

420 Saw Mill River Road
ARDSLEY, NY 10502
United States - Map
+1-914-3474300 (Phone)
+1-914-3474560 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system. Ampyra (dalfampridine) is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP). It also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a short-acting drug for the management of spasticity. Ampyra is marketed as Fampyra outside the United States by Biogen Idec International GmbH (Biogen Idec). On February 6, 2012, the Company launched tizanidine hydrochloride capsules, an authorized generic version of Zanaflex Capsules under an agreement with Watson Pharma, Inc. In December 2012, the Company acquired Neuronex, Inc.

Officers and directors

Ron Cohen M.D. President,Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Michael W. Rogers Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Lauren M. Sabella Executive Vice President - Commercial Development
Age: 53
Bio & Compensation  - Reuters
Andrew R. Blight Ph.D. Chief Scientific Officer
Age: 63
Bio & Compensation  - Reuters
Jane Wasman J.D. President - International, General Counsel, Corporate Secretary
Age: 57
Bio & Compensation  - Reuters
Enrique J. Carrazana M.D. Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Andrew Asa Hindman Chief Business Development Officer
Bio & Compensation  - Reuters
David W. Lawrence Chief - Business Operations
Age: 56
Bio & Compensation  - Reuters
Barry E. Greene Independent Director
Age: 50
Bio & Compensation  - Reuters
Peder K. Jensen M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters